StockGuru Shines its Spotlight on American CryoStem Corporation (OTCBB: CRYO) Upon the Announcement of Patent Grant by USPTO — September 2, 2011

StockGuru Shines its Spotlight on American CryoStem Corporation (OTCBB: CRYO) Upon the Announcement of Patent Grant by USPTO — September 2, 2011

Dallas, Texas (September 2, 2011) – StockGuru Shines its Spotlight on American CryoStem Corporation (OTCBB: CRYO) announced yesterday the grant to it of a patent by the United States Patent Office (USPTO).  The Company closed on September 1, 2011, at $2.20, trading in a fifty-two week range of $3.75 – 0.25.

American CryoStem Corporation (the “Company”) has been awarded U.S. Patent Number 7,989,205, entitled “Cell Culture Media, Kits, and Methods of Use” (the “Patent”), by the USPTO. This Patent covers a unique product for cellular growth in the processing of adult stem cells. This is significant to the Company for the advancement of its research, clinical and cosmetic applications. The Company’s management believes that the Patent will support the Company’s efforts in its goal to establish itself as a leader in the preparation of autologous stem cells for use in regenerative medicine. The Patent includes a specific human formulation to overcome the concerns and issues prevalent in the FDA’s and other regulatory agencies’ guidance when using non-human biologic materials in the preparation of stem cells for human use.

John S Arnone, CEO, stated, “We are pleased to have the Patent granted to the Company by the USPTO. We believe the Patent will be instrumental to the industry based on its cellular growth properties and absence of non-human biologic material. Further, as stem cell and regenerative medicine advances in the United States, as it has globally, the Company is confident the Patent, together with our core technology and our intellectual property regarding methods, formulations, devices and products will allow us to enter into additional partnerships and collaborations with other industry participants. The Patent validates our corporate direction and enhances our strategy to obtain strong intellectual property protection.”

Anthony Dudzinski, COO, stated, “We believe the Patent on specie specific media gives the Company a unique market position by alleviating the significant regulatory requirements associated with products containing fetal bovine serum or other non-human biologic components. The Patent is important and will accelerate the development and commercialization of additional Company products and services. We are excited and very optimistic regarding our place in the stem cell industry and the value of our products and services.”

About American CryoStem: The Company markets a core clinical processing platform for Adipose (fat) Derived Adult Stem Cells. The Company’s services provide for the collection, processing, and cryopreservation (long term storage) of adult stem cells, allowing healthy individuals to privately preserve their stem cells for future use in personalized and regenerative medicine at an affordable price. Adult stem cell treatments are currently being utilized to potentially heal one’s own body of diseases and chronic conditions. The Company’s proprietary platform provides streamlined and affordable processing and cryopreservation of Adipose Derived Stem Cells and Adipose Tissue for autologous (self) use.

 

To view this StockGuru Spotlight, please visit: http://www.stockguru.com/category/latest-spotlights/

To get free alerts on this and other similar stocks, please register here:

http://www.stockguru.com/?page_id=250

What is the StockGuru Spotlight?

Many companies covered in The StockGuru Spotlight have positive increases in both volume and share price. While this is not true in all cases, StockGuru strives to cover companies in The StockGuru Spotlight that are worth of our readers’ attention.

StockGuru looks for potential break-out candidates in The StockGuru Spotlight.  Many of these companies have had recent news and appear to be getting the attention of investors. StockGuru does not typically feature companies in The StockGuru Spotlight that are compensating StockGuru for this coverage.  There are times when StockGuru covers a stock in The StockGuru Spotlight that had previously compensated Stockguru. Where that is the case, a proper disclosure is included below.   StockGuru and its partners, employees and writers never hold shares, short positions, warrants or any other current position in a stock featured in The StockGuru Spotlight.

To feature a company in The StockGuru Spotlight please contact the Publisher at publisher@stockguru.com.  If our reader is a key person for a publicly traded company, StockGuru can consider that company for either a StockGuru Spotlight or a StockGuru Profile.  Please contact the StockGuru Publisher John Pentony at this email address:  john@stockguru.com.

Stockguru.com (“SG”) provides its members with the latest news, press releases, and trade alerts for all the companies highlighted on the site StockGuru.com. SG utilizes information believed to be reliable herein prepared all material. The information contained herein is not guaranteed by SG to be accurate, and should not be considered to be all-inclusive. The owner, publisher, editor and their associates are not responsible for errors and omissions.  SG encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and SG makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. SG is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on http://www.Stockguru.com or mentioned herein.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected”, “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and SG undertakes no obligation to update such statements. StockGuru is occasionally compensated for coverage.  When this is the case, SG clearly indicates this with a disclosure of all compensation received in the past and present.  Additionally SG also discloses any anticipated compensation in the future.  Compensation is typically in cash.  Sometimes a company pays SG in restricted shares. Pentony Enterprise and its associated companies does not take free trading shares for any reason at anytime. StockGuru is not a registered investment adviser or a broker-dealer. StockGuru makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.

John Pentony, Publisher, Stockguru.com

Tel: +1 469 252 3031

e-mail: john@stockguru.com